Evidence map›Paper›PMID 35020136›Full record

ArticleJournal of cancer survivorship : research and practice2022

Childhood cancer survivorship care during the COVID-19 pandemic: an international report of practice implications and provider concerns.

Selina R van den Oever, Saskia M F Pluijm, Rod Skinner, Adam Glaser, Renée L Mulder, Saro Armenian, Edit Bardi, Claire Berger, Matthew J Ehrhardt, Jordan Gilleland Marchak and 23 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 22 countries.

Selina R van den OeverPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands. s.r.vandenoever-2@prinsesmaximacentrum.nl.
Saskia M F PluijmPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
Rod SkinnerGreat North Children's Hospital, and Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
Adam GlaserLeeds Institute of Medical Research, University of Leeds, Leeds, LS2 9JT, UK.
Renée L MulderPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
Saro ArmenianCity of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Edit BardiSt Anna Childrens Hospital, Vienna, Austria.
Claire BergerDepartment for Pediatric Hematology and Oncology CHU Nord, University Hospital Saint-Etienne, Saint-Priest en Jarez, France.
Matthew J EhrhardtDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jordan Gilleland MarchakDepartment of Pediatrics at, Emory University School of Medicine, Aflac Cancer & Blood Disorders Center at Children's Healthcare of Atlanta, Atlanta, GA, USA.
Gabrielle M HaeuslerPaediatric Integrated Cancer Centre, Victoria, Australia.
Jaap den HartoghDutch Childhood Cancer Parent Organization VOKK Netherlands, Department VOX Survivors, Nieuwegein, The Netherlands.
Lars HjorthDepartment of Paediatrics, Skåne University Hospital Clinical Sciences, Lund University, Lund, Sweden.
Tomas KepakUniversity Hospital Brno & International Clinical Research Center (FNUSA-ICRC), Masaryk University, Brno, Czech Republic.
Izolda KrivieneRepublican Siauliai County Hospital, Siauliai, Lithuania.
Thorsten LangerPediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Miho MaedaDepartment of Pediatrics, Nippon Medical School, Tokyo, Japan.
Catalina Márquez-VegaDepartment of Pediatric Oncology, Hospital Virgen del Rocío, Sevilla, Spain.
Gisela MichelDepartment of Health Sciences and Medicine, University of Lucerne, Frohburgstrasse 3, PO Box 4466, 6002, Lucerne, Switzerland.
Monica MuracaEpidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Mohamed NajibHospital Tunku Azizah, Kuala Lumpur, Malaysia.
Paul C NathanDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
Anna PanasiukDepartment of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland.
Maya PrasadPaediatric Oncology, Tata Memorial Hospital, Mumbai, India.
Jelena RoganovicDepartment of Pediatrics, Clinical Hospital Centre Rijeka and School of Medicine of the University of Rijeka, Rijeka, Croatia.
Anne UyttebroeckDepartment of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium.
Jeanette F WintherDanish Cancer Society Research Center, Copenhagen, Denmark.
Lorna Zadravec ZaletelRadiotherapy department, Institute of Oncology, Zaloska 2, 1000, Ljubljana, Slovenia.
Elvira C van DalenPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
Helena J H van der PalPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
Melissa M HudsonDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Leontien C M KremerPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
IGHG COVID-19 working group
Princess Máxima Center · NLSt. Jude Children's Research Hospital · USAarhus University Hospital · DKAmsterdam University Medical Centers · NLCity of Hope · USDuchenne Parent Project · NLEmory University · USGreat North Children's Hospital · GBHospital for Sick Children · CAHospital Kuala Lumpur · MYHospital Universitario Virgen del Rocío · ESInstitute of Oncology Ljubljana · SIInternational Clinical Research Center, St. Anne's University Hospital Brno · CZIstituto Giannina Gaslini · ITKU Leuven · BELund University · SENippon Medical School · JPRoyal Children's Hospital · AUŠiauliai University · LTSt Anna Children's Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLong-term follow-up (LTFU) care is essential to optimise health outcomes in childhood cancer survivors (CCS). We aimed to assess the impact of the COVID-19 pandemic on LTFU services and providers.

methodsA COVID-19 working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) distributed a questionnaire to LTFU service providers in 37 countries across Europe, Asia, North America, Central/South America, and Australia. The questionnaire assessed how care delivery methods changed during the pandemic and respondents' level of worry about the pandemic's impact on LTFU care delivery, their finances, their health, and that of their family and friends.

resultsAmong 226 institutions, providers from 178 (79%) responded. Shortly after the initial outbreak, 42% of LTFU clinics closed. Restrictions during the pandemic resulted in fewer in-person consultations and an increased use of telemedicine, telephone, and email consultations. The use of a risk assessment to prioritise the method of LTFU consultation for individual CCS increased from 12 to 47%. While respondents anticipated in-person consultations to remain the primary method for LTFU service delivery, they expected significantly increased use of telemedicine and telephone consultations after the pandemic. On average, respondents reported highest levels of worry about psychosocial well-being of survivors.

conclusionsThe pandemic necessitated changes in LTFU service delivery, including greater use of virtual LTFU care and risk-stratification to identify CCS that need in-person evaluations. IMPLICATIONS FOR CANCER SURVIVORS: Increased utilisation of virtual LTFU care and risk stratification is likely to persist post-pandemic.

Indexed as

Cancer SurvivorsCOVID-19NeoplasmsChildHumansPandemicsSurvivorsChildhood cancerCOVID-19Long-term follow-up carePaediatric oncology

Identifiers

PMID35020136
PMCPMC8753338
OpenAlexW4205166710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.